SynthesisWorld journal of surgical oncology2025
Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with colorectal cancer: a meta-analysis.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effect of soluble programmed cell death 1 ligand 1 (sPD-L1) on the prognosis of colorectal cancer (CRC) has been extensively explored; however, the results remain controversial. Therefore, we performed a meta-analysis to determine its exact function in predicting CRC prognosis.
methodsWe retrieved relevant data from the Web of Science, PubMed, Embase, and Cochrane Library databases from their inception to February 24, 2025. We computed combined hazard ratios (HRs) and 95% confidence intervals (CIs) to estimate the value of sPD-L1 in predicting overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in CRC.
resultsSix studies involving a total of 773 patients were included. The integrated results revealed that higher sPD-L1 levels were significantly associated with unfavorable OS (HR = 2.19, 95%CI = 1.16‒4.15; p = 0.016) and DFS/PFS (HR = 3.14, 95%CI = 1.88‒5.24; p < 0.001) in CRC. However, sPD-L1 was not markedly associated with sex (OR = 1.28, 95%CI = 0.52-3.14; p = 0.596), T stage (OR = 0.65, 95%CI = 0.33‒1.28; p = 0.210), TNM stage (OR = 0.99, 95%CI = 0.57‒1.74; p = 0.976) and lymph node metastasis (OR = 0.86, 95%CI = 0.46‒1.58; p = 0.620) in CRC.
conclusionsElevated sPD-L1 levels could serve as a critical factor in predicting both unfavorable OS and DFS/PFS in patients with CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.